The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.
 
Jia Luo
Honoraria - Physicans' Education Resource; Targeted Oncology; VJOncology
Consulting or Advisory Role - AstraZeneca
Research Funding - Erasca, Inc; Genentech; Kronos Bio; Novartis; Revolution Medicines
Travel, Accommodations, Expenses - Blueprint Medicines; Daiichi Sankyo; Erasca, Inc
 
Elinton Lee
No Relationships to Disclose
 
Michelle Sanchez
No Relationships to Disclose
 
Bryanna Finstein
No Relationships to Disclose
 
Hans Hertzler
No Relationships to Disclose
 
Nhi Luong
Employment - Novartis
 
Rubii Tamen
No Relationships to Disclose
 
Tom Nguyen
No Relationships to Disclose
 
Paul K. Paik
Honoraria - Bicara Therapeutics; Crown Bioscience; EMD Serono; Janssen Oncology; Mirati Therapeutics; Takeda
Consulting or Advisory Role - Bicara Therapeutics; Crown Bioscience; EMD Serono; Janssen Oncology; Mirati Therapeutics; Takeda
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Merck; Novartis; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Sarina A. Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immorna (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Jiangsu Simcere Pharmaceutical Co. Ltd. (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synlogic (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); ZielBio (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Duality Biologics; Eisai; Frontier Medicines; Hongyun Biotech; Ignyta; Lilly; LOXO; Merrimack; Merus; Mirati Therapeutics; Monte Rosa Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; Scorpion Therapeutics; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Lynette M. Sholl
Stock and Other Ownership Interests - Moderna Therapeutics (I)
Consulting or Advisory Role - AstraZeneca; Genentech (Inst); Lilly (Inst)
Research Funding - Bristol Myers Squibb (Inst); Roche/Genentech (Inst)
 
Michael L. Cheng
Honoraria - Lynx Group; Potomac Center for Medical Education; WebMD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Inivata; Mirati Therapeutics
Research Funding - Palleon Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Genzyme
 
Steven G. DuBois
Consulting or Advisory Role - Amgen; Bayer; Jazz Pharmaceuticals
Research Funding - Bayer (Inst); BMS (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi; SIRPant Immunotherapeutics
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP
 
Mizuki Nishino
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Toshiba (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - Artios; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Fusion Pharmaceuticals; ImmunoMet; Janssen Oncology; Kymera; Lilly; Merck Serono; Pfizer; Syros Pharmaceuticals; Xinthera; Zentalis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb/Medarex (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Cyclacel (Inst); Cyteir (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
 
Christopher Alexander French
Research Funding - Epigenetix (Inst)